United States CAR-T Cell Therapy Market is expected to reach US$ 20.4 billion by 2033 | Top key players - Novartis AG, Gilead Sciences, Inc., Bristol Myers Squibb Company.

Market Size and Growth:

The Global CAR-T Cell Therapy Market size reached US$ 4.8 billion in 2024 and is expected to reach US$ 20.4 billion by 2033, growing at a CAGR of 16.3% during the forecast period 2025-2033.

The CAR-T Cell Therapy Market report, published by DataM Intelligence, provides in-depth insights and analysis on key market trends, growth opportunities, and emerging challenges. Committed to delivering actionable intelligence, DataM Intelligence empowers businesses to make informed decisions and stay ahead of the competition. Through a combination of qualitative and quantitative research methods, it offers comprehensive reports that help clients navigate complex market landscapes, drive strategic growth, and seize new opportunities in an ever-evolving global market.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID): https://datamintelligence.com/download-sample/car-t-cell-therapy-market?sz

The CAR-T Cell Therapy Market encompasses the development, production, and commercialization of chimeric antigen receptor T-cell therapies, a form of immunotherapy that engineers patients' T-cells to target and destroy cancer cells. It includes applications in hematologic cancers, research advancements, clinical trials, and regulatory approvals, driven by rising cancer prevalence, personalized medicine demand, and technological innovations in cell engineering.

Industry Recent Developments:

United States:
In August 2025, Gilead Sciences' Kite Pharma announced the acquisition of Interius BioTherapeutics for $350 million to enhance Kite's CAR-T cell therapy pipeline with an innovative in-vivo delivery platform simplifying treatment via intravenous infusion.

In July 2025, the CAR T Vision Coalition launched an initiative to double the number of patients treated with CAR-T cell therapies by 2030, aiming to expand access to these treatments for advanced blood cancers.

Japan:
In July 2025, Japan's CAR-T cell therapy market was forecasted to nearly double by 2030, driven by advancements in automated manufacturing and technologies supporting allogeneic (off-the-shelf) CAR-T therapies, expanding treatment accessibility.

In May 2025, Cellares and Mitsui Fudosan began construction of Japan's first next-generation commercial production site for CAR-T therapies in Kashiwa City, aiming to scale up production and improve patient access.

Europe:
In October 2025, the European CAR-T platform sector is growing with increased investments and collaborations in biopharma and startups, especially with cancer and rare disease prevalence driving demand.

In May 2024, German Cancer Aid awarded a 2.6 million euro grant to support innovative clinical studies using stem-like CAR-T cells for advanced lymphomas in Germany, boosting research and treatment innovations.

Speak to Our Analyst and Get Customization in the report as per your requirements: https://datamintelligence.com/customize/car-t-cell-therapy-market?sz

Major Key Players:

Novartis AG
Gilead Sciences, Inc.
Bristol Myers Squibb company
Johnson & Johnson
Autolus Therapeutics
Pfizer Inc.
BioNTech SE.
Merck KGaA
Allogene Therapeutics
Atara Biotherapeutics, Inc.

Key Growth Drivers:

Increasing Incidence of Cancer: The rising number of cancer cases globally, particularly blood cancers like leukemia and lymphoma, drives the demand for CAR-T cell therapies as effective treatment options.

Advances in Biotechnology: Innovations in genetic engineering and cell therapy techniques have improved the efficacy and safety of CAR-T therapies, fueling market growth.

Growing Investment and Collaborations: Significant funding from pharmaceutical companies, government initiatives, and collaborations between biotech firms and research institutions accelerate research, development, and commercialization of CAR-T therapies, expanding the market.

Segments Covered in the CAR-T Cell Therapy Market:

By Therapy Type: Autologous CAR-T Cell Therapy, Allogeneic CAR-T Cell Therapy.

By Drug Type: Abecma, Breyanzi, Carvykti, Tecartus, Kymriah, Yescarta.

By Target Antigen: CD19, BCMA (B-cell maturation antigen), CD20, CD22, CD30, CD33, GD2, HER2, Others.

Regional Analysis:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Looking For Full Report? Get it Here: https://www.datamintelligence.com/buy-now-page?report=car-t-cell-therapy-market

Chapter Outline

⏩ Market Overview: It contains five chapters, as well as information about the research scope, major manufacturers covered, market segments, CAR-T Cell Therapy market segments, study objectives, and years considered.

⏩ Market Landscape: The competition in the Global CAR-T Cell Therapy Market is evaluated here in terms of value, turnover, revenues, and market share by organization, as well as market rate, competitive landscape, and recent developments, transaction, growth, sale, and market shares of top companies.

⏩ Companies Profiles: The Global CAR-T Cell Therapy market's leading players are studied based on sales, main products, gross profit margin, revenue, price, and growth production.

⏩ Market Outlook by Region: The report goes through gross margin, sales, income, supply, market share, CAGR, and market size by region in this segment. North America, Europe, Asia Pacific, Middle East & Africa, and South America are among the regions and countries studied in depth in this study.

⏩ Market Segments: It contains the deep research study which interprets how different end-user/application/type segments contribute to the CAR-T Cell Therapy Market.

⏩ Market Forecast: Production Side: In this part of the report, the authors have focused on production and production value forecast, key producers forecast, and production and production value forecast by type.

⏩ Research Findings: This section of the report showcases the findings and analysis of the report.

⏩ Conclusion: This portion of the report is the last section of the report where the conclusion of the research study is provided.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription

People Also Ask:

◆ How big is the CAR-T Cell Therapy Market in 2025?
◆ What is the projected growth rate of the CAR-T Cell Therapy Market through 2033?
◆ Who are the key players in the CAR-T Cell Therapy Market?
◆ Which region is expected to dominate the industry during the forecast period?

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.